Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis.

Liu D, Lehmann HP, Frick KD, Carter HB.

J Urol. 2012 Apr;187(4):1241-6. doi: 10.1016/j.juro.2011.12.015. Epub 2012 Feb 14.

2.

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.

JAMA. 2010 Dec 1;304(21):2373-80. doi: 10.1001/jama.2010.1720. Erratum in: JAMA. 2011 May 11;305(18):1862.

3.

The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer.

Koerber F, Waidelich R, Stollenwerk B, Rogowski W.

BMC Health Serv Res. 2014 Apr 10;14:163. doi: 10.1186/1472-6963-14-163.

4.

Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.

Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ.

Cancer. 2007 Nov 15;110(10):2210-7.

5.

Clinical management and burden of prostate cancer: a Markov Monte Carlo model.

Sanyal C, Aprikian A, Cury F, Chevalier S, Dragomir A.

PLoS One. 2014 Dec 4;9(12):e113432. doi: 10.1371/journal.pone.0113432. eCollection 2014.

6.

Prostate cancer screening: a decision analysis.

Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM.

J Fam Pract. 1995 Jul;41(1):33-41.

PMID:
7798064
7.

Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer.

Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB.

J Urol. 2012 May;187(5):1620-5. doi: 10.1016/j.juro.2011.12.072. Epub 2012 Mar 14.

PMID:
22425079
8.

Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.

Parikh R, Sher DJ.

Cancer. 2012 Jan 1;118(1):258-67. doi: 10.1002/cncr.26272. Epub 2011 Jun 30.

9.

Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations.

Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM.

Ann Intern Med. 1998 Nov 15;129(10):787-96.

PMID:
9841584
10.

Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.

Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV.

Cancer. 2013 May 15;119(10):1808-15. doi: 10.1002/cncr.27980. Epub 2013 Feb 7. Erratum in: Cancer. 2013 Jun 15;119(12):2358. Dosage error in article text.

11.

A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.

Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE.

JAMA. 1993 May 26;269(20):2650-8.

PMID:
8487449
12.

Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.

Bratt O, Folkvaljon Y, Hjälm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P.

Eur Urol. 2015 Jul;68(1):53-8. doi: 10.1016/j.eururo.2014.12.026. Epub 2015 Mar 23.

13.

Do older men benefit from curative therapy of localized prostate cancer?

Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD.

J Clin Oncol. 2003 Sep 1;21(17):3318-27.

PMID:
12947068
14.

Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer.

Davison BJ, Oliffe JL, Pickles T, Mroz L.

Oncol Nurs Forum. 2009 Jan;36(1):89-96. doi: 10.1188/09.ONF.89-96.

PMID:
19136342
15.

A decision analysis for treatment of clinically localized prostate cancer.

Kattan MW, Cowen ME, Miles BJ.

J Gen Intern Med. 1997 May;12(5):299-305.

16.

Pilot study of a utilities-based treatment decision intervention for prostate cancer patients.

Knight SJ, Nathan DP, Siston AK, Kattan MW, Elstein AS, Collela KM, Wolf MS, Slimack NS, Bennett CL, Golub RM.

Clin Prostate Cancer. 2002 Sep;1(2):105-14.

PMID:
15046701
17.

Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example.

Elkin EB, Cowen ME, Cahill D, Steffel M, Kattan MW.

Med Decis Making. 2004 Sep-Oct;24(5):504-10.

PMID:
15358999
18.

Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.

Zubek VB, Konski A.

Mol Diagn Ther. 2009;13(1):31-47. doi: 10.2165/01250444-200913010-00006.

PMID:
19351214
19.

Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.

Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK.

BJU Int. 2013 Mar;111(3):437-50. doi: 10.1111/j.1464-410X.2012.11597.x. Epub 2012 Dec 28.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk